PET-CT Used for Lung Cancer Diagnosis May Be Less Effective in Areas Where Infectious Lung Disease Is More Common
By MedImaging International staff writers Posted on 08 Oct 2014 |
An analysis of data gleaned from 70 studies revealed that use of the diagnostic imaging modality fluorodeoxyglucose F18 (FDG)-positron emission tomography (PET) combined with computed tomography (CT) may not effectively differentiate benign disease from lung cancer in patients with endemic (high prevalence) infectious lung disease compared with nonendemic regions, according to recent research.
The findings were published September 24, 2014, in the Journal of the American Medical Association (JAMA). Depending on the risk for cancer, diagnostic guidelines suggest or advise to use FDG combined with PET as a noninvasive imaging modality to evaluate the risk of cancer or benign disease.
Stephen A. Deppen, PhD, from the Tennessee Valley Healthcare System and Vanderbilt University Medical Center (Nashville, TN, USA) and colleagues conducted a meta-analysis to assess the accuracy of FDG-PET to identify lung lesions in regions with locally endemic infectious lung diseases. The researchers identified 70 studies that met criteria for inclusion in the analysis. The studies reported on a total of 8,511 nodules; 5,105 (60%) were malignant.
Pooled sensitivity of FDG-PET for detecting lung cancer was 89% and pooled specificity was 75%. There was a 16% lower average adjusted specificity in regions with endemic infectious lung disease (61%) compared with nonendemic regions (77%). Lower specificity was seen when the analysis was limited to rigorously conducted and well-controlled studies.
“FDG-PET for the diagnosis of lung cancer in patients who reside in a region with significant endemic infectious lung disease should be recognized as having lower specificity than previously reported. Knowledge of this reduction in specificity should limit the use of FDG-PET to diagnose lung cancer unless substantial institutional expertise in FDG-PET interpretation has been proven. Should low-dose CT screening for lung cancer become the diagnostic standard, knowledge of FDG-PET/CT performance is even more critical because the vast majority of indeterminate lung nodules detected through screening are benign,” the authors wrote in their article.
Related Links:
Vanderbilt University Medical Center
The findings were published September 24, 2014, in the Journal of the American Medical Association (JAMA). Depending on the risk for cancer, diagnostic guidelines suggest or advise to use FDG combined with PET as a noninvasive imaging modality to evaluate the risk of cancer or benign disease.
Stephen A. Deppen, PhD, from the Tennessee Valley Healthcare System and Vanderbilt University Medical Center (Nashville, TN, USA) and colleagues conducted a meta-analysis to assess the accuracy of FDG-PET to identify lung lesions in regions with locally endemic infectious lung diseases. The researchers identified 70 studies that met criteria for inclusion in the analysis. The studies reported on a total of 8,511 nodules; 5,105 (60%) were malignant.
Pooled sensitivity of FDG-PET for detecting lung cancer was 89% and pooled specificity was 75%. There was a 16% lower average adjusted specificity in regions with endemic infectious lung disease (61%) compared with nonendemic regions (77%). Lower specificity was seen when the analysis was limited to rigorously conducted and well-controlled studies.
“FDG-PET for the diagnosis of lung cancer in patients who reside in a region with significant endemic infectious lung disease should be recognized as having lower specificity than previously reported. Knowledge of this reduction in specificity should limit the use of FDG-PET to diagnose lung cancer unless substantial institutional expertise in FDG-PET interpretation has been proven. Should low-dose CT screening for lung cancer become the diagnostic standard, knowledge of FDG-PET/CT performance is even more critical because the vast majority of indeterminate lung nodules detected through screening are benign,” the authors wrote in their article.
Related Links:
Vanderbilt University Medical Center
Latest Nuclear Medicine News
- New PET Biomarker Predicts Success of Immune Checkpoint Blockade Therapy
- New PET Agent Rapidly and Accurately Visualizes Lesions in Clear Cell Renal Cell Carcinoma Patients
- New Imaging Technique Monitors Inflammation Disorders without Radiation Exposure
- New SPECT/CT Technique Could Change Imaging Practices and Increase Patient Access
- New Radiotheranostic System Detects and Treats Ovarian Cancer Noninvasively
- AI System Automatically and Reliably Detects Cardiac Amyloidosis Using Scintigraphy Imaging
- Early 30-Minute Dynamic FDG-PET Acquisition Could Halve Lung Scan Times
- New Method for Triggering and Imaging Seizures to Help Guide Epilepsy Surgery
- Radioguided Surgery Accurately Detects and Removes Metastatic Lymph Nodes in Prostate Cancer Patients
- New PET Tracer Detects Inflammatory Arthritis Before Symptoms Appear
- Novel PET Tracer Enhances Lesion Detection in Medullary Thyroid Cancer
- Targeted Therapy Delivers Radiation Directly To Cells in Hard-To-Treat Cancers
- New PET Tracer Noninvasively Identifies Cancer Gene Mutation for More Precise Diagnosis
- Algorithm Predicts Prostate Cancer Recurrence in Patients Treated by Radiation Therapy
- Novel PET Imaging Tracer Noninvasively Identifies Cancer Gene Mutation for More Precise Diagnosis
- Ultrafast Laser Technology to Improve Cancer Treatment